AR032553A1 - Derivados de alfa-amino-n-hidroxi-acetamida. - Google Patents
Derivados de alfa-amino-n-hidroxi-acetamida.Info
- Publication number
- AR032553A1 AR032553A1 ARP020100398A ARP020100398A AR032553A1 AR 032553 A1 AR032553 A1 AR 032553A1 AR P020100398 A ARP020100398 A AR P020100398A AR P020100398 A ARP020100398 A AR P020100398A AR 032553 A1 AR032553 A1 AR 032553A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- amino
- triazol
- acetamide
- hydroxi
- Prior art date
Links
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- -1 1,2,3 -triazol-2-yl Chemical group 0.000 abstract 1
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 abstract 1
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- VDBCTDQYMZSQFQ-UHFFFAOYSA-N glycine hydroxamate Chemical class NCC(=O)NO VDBCTDQYMZSQFQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La presente se refiere a derivados de alfa-amino-N-hidroxi-acetamida de la formula (1), en donde: R es dialquilamino inferior-amino, 1,2,3-triazol-1-ilo, 1,2,3-triazol-2-ilo, o 1,2,4-triazol-4-ilo, m representa un entero de hasta e incluyendo 10, y n representa un entero de 0 hasta e incluyendo 10, o una sal de los mismos; a procesos para su preparacion, a composiciones farmacéuticas que comprenden estos derivados del ácido hidroxámico, al uso de estos derivados del ácido hidroxámico como medicamentos y a un método para el tratamiento de condiciones o enfermedades mediadas por las metaloproteinasas degradantes de matriz (MMP) utilizando estos derivados solos o en combinacion con uno o más agentes terapéuticos diferentes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0103303.4A GB0103303D0 (en) | 2001-02-09 | 2001-02-09 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR032553A1 true AR032553A1 (es) | 2003-11-12 |
Family
ID=9908475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020100398A AR032553A1 (es) | 2001-02-09 | 2002-02-07 | Derivados de alfa-amino-n-hidroxi-acetamida. |
Country Status (10)
Country | Link |
---|---|
US (3) | US7112611B2 (es) |
EP (1) | EP1360175A1 (es) |
JP (1) | JP4262982B2 (es) |
CN (1) | CN100509773C (es) |
AR (1) | AR032553A1 (es) |
AU (1) | AU2002249197A1 (es) |
CA (1) | CA2435611C (es) |
GB (1) | GB0103303D0 (es) |
PE (1) | PE20020845A1 (es) |
WO (1) | WO2002064552A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
GB0103303D0 (en) * | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
WO2005090297A1 (en) * | 2004-03-19 | 2005-09-29 | Biotie Therapies Corporation | Sulphonamide derivatives |
BRPI0709677A2 (pt) * | 2006-03-29 | 2011-07-19 | Novartis Ag | inibidores seletivos das mmp à base de hidroxamato |
US20100234378A1 (en) * | 2006-08-22 | 2010-09-16 | Array Biopharma Inc. | Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors |
WO2008147764A1 (en) * | 2007-05-23 | 2008-12-04 | Array Biopharma, Inc. | Mmp inhibitors and methods of use thereof |
EP2934555B1 (en) | 2012-12-21 | 2021-09-22 | Astellas Institute for Regenerative Medicine | Methods for production of platelets from pluripotent stem cells |
US20180353175A1 (en) * | 2017-06-13 | 2018-12-13 | Ethicon Llc | Surgical Fastener with Broad Spectrum MMP Inhibitors |
US11058804B2 (en) | 2017-06-13 | 2021-07-13 | Ethicon Llc | Surgical fastener device for the prevention of ECM degradation |
CN110769866B (zh) * | 2017-06-13 | 2022-07-29 | 爱惜康有限责任公司 | 具有可控愈合的外科缝合器 |
US10939911B2 (en) | 2017-06-13 | 2021-03-09 | Ethicon Llc | Surgical stapler with end effector coating |
CN110740764B (zh) * | 2017-06-13 | 2022-05-27 | 爱惜康有限责任公司 | 具有广谱mmp抑制剂的外科紧固件 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2513826A (en) * | 1946-12-05 | 1950-07-04 | Gen Aniline & Film Corp | Aromatic sulfonhydrazides |
US4772733A (en) | 1986-07-17 | 1988-09-20 | Hercules Incorporated | Epoxy-azides |
US4806528A (en) * | 1987-09-04 | 1989-02-21 | Hanreich Reinhard G | Process for the preparation of 2-(2-chloroethoxy)-benzenesulfonamide |
US5338755A (en) * | 1990-07-31 | 1994-08-16 | Elf Sanofi | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present |
FR2682498A1 (fr) * | 1991-10-15 | 1993-04-16 | Kodak Pathe | Colorants comprenant des macrocycles thioethers. |
US5663431A (en) * | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5646167A (en) | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9503749D0 (en) * | 1995-02-24 | 1995-04-12 | British Biotech Pharm | Synthesis of hydroxamic acid derivatives |
CA2242416C (en) * | 1996-01-23 | 2006-03-21 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
NZ325939A (en) | 1996-01-23 | 2000-06-23 | Shionogi & Co | Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives |
WO1997044315A1 (en) | 1996-05-17 | 1997-11-27 | Warner-Lambert Company | Biphenylsulfonamide matrix metalloproteinase inhibitors |
WO1997045402A1 (fr) | 1996-05-24 | 1997-12-04 | Ono Pharmaceutical Co., Ltd. | Derives de phenylsulfonamide |
WO1998018754A1 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
IL128545A0 (en) | 1996-12-09 | 2000-01-31 | Warner Lambert Co | Method for treating and preventing heart failure and ventricular dilatation |
ID22799A (id) | 1997-02-03 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan asam arilsulfonilamino hidroksamat |
GB9708133D0 (en) | 1997-04-22 | 1997-06-11 | British Biotech Pharm | Novel use of matrix metalloproteinase inhibitors |
ES2165640T3 (es) | 1997-05-09 | 2002-03-16 | Hoechst Ag | Acidos diaminocarboxilicos sustituidos. |
DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
WO1999006340A2 (en) | 1997-07-31 | 1999-02-11 | The Procter & Gamble Company | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
IL127496A0 (en) | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
NZ505968A (en) | 1998-02-04 | 2003-03-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases |
JPH11236369A (ja) | 1998-02-23 | 1999-08-31 | Kotobuki Seiyaku Kk | スルホンアミド誘導体及びその製造法並びにこれを含有する医薬組成物 |
PA8469301A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Procedimientos para la preparacion de acidos hidroxamicos. |
RU2232751C2 (ru) | 1998-12-22 | 2004-07-20 | Ф.Хоффманн-Ля Рош Аг | Производные сульфонамидов и фармацевтическая композиция |
AR035311A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento |
AR035313A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos. |
GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
GB0103303D0 (en) * | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
-
2001
- 2001-02-09 GB GBGB0103303.4A patent/GB0103303D0/en not_active Ceased
-
2002
- 2002-02-07 PE PE2002000088A patent/PE20020845A1/es not_active Application Discontinuation
- 2002-02-07 AR ARP020100398A patent/AR032553A1/es unknown
- 2002-02-08 US US10/467,611 patent/US7112611B2/en not_active Expired - Fee Related
- 2002-02-08 WO PCT/EP2002/001345 patent/WO2002064552A1/en active Application Filing
- 2002-02-08 CN CNB028047133A patent/CN100509773C/zh not_active Expired - Fee Related
- 2002-02-08 JP JP2002564485A patent/JP4262982B2/ja not_active Expired - Fee Related
- 2002-02-08 EP EP02718115A patent/EP1360175A1/en not_active Withdrawn
- 2002-02-08 AU AU2002249197A patent/AU2002249197A1/en not_active Abandoned
- 2002-02-08 CA CA2435611A patent/CA2435611C/en not_active Expired - Fee Related
-
2006
- 2006-08-07 US US11/500,138 patent/US7291634B2/en not_active Expired - Fee Related
-
2007
- 2007-10-05 US US11/868,032 patent/US7659293B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002064552A1 (en) | 2002-08-22 |
GB0103303D0 (en) | 2001-03-28 |
JP2004523545A (ja) | 2004-08-05 |
US20040082630A1 (en) | 2004-04-29 |
US7112611B2 (en) | 2006-09-26 |
CN100509773C (zh) | 2009-07-08 |
WO2002064552A8 (en) | 2002-12-12 |
CA2435611C (en) | 2011-07-12 |
EP1360175A1 (en) | 2003-11-12 |
AU2002249197A1 (en) | 2002-08-28 |
US7291634B2 (en) | 2007-11-06 |
US20080176916A1 (en) | 2008-07-24 |
JP4262982B2 (ja) | 2009-05-13 |
US20060270719A1 (en) | 2006-11-30 |
CN1525956A (zh) | 2004-09-01 |
US7659293B2 (en) | 2010-02-09 |
PE20020845A1 (es) | 2002-10-30 |
CA2435611A1 (en) | 2002-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0410979A (pt) | composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia | |
DK1361882T3 (da) | 4-fluor-N-indan-2-ylbenzamid og dets anvendelse som farmaceutisk middel | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
ECSP066312A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
SE0200979D0 (sv) | New compounds | |
UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
PE20030823A1 (es) | Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo | |
ATE381535T1 (de) | Phenethanolaminderivate | |
CU23105A3 (es) | DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS | |
NO20062905L (no) | Nye hydroksaminsyreestere og farmasoytisk anvendelse derav | |
UY27169A1 (es) | Derivados del ácido isoftálico como inhibidores de metalproteinasas de la matriz | |
UY30438A1 (es) | Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos | |
BR9910849A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido. | |
UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
BR112023020442A2 (pt) | Inibidor da protease 1 específica de ubiquitina (usp1) | |
GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
AR032553A1 (es) | Derivados de alfa-amino-n-hidroxi-acetamida. | |
ECSP034883A (es) | Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen | |
SE0100569D0 (sv) | New compounds | |
AR051797A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
BR0307588A (pt) | Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença | |
PE20040961A1 (es) | Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel | |
BRPI0408689A (pt) | derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor | |
AR001769A1 (es) | Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |